Gilead upgraded by Morgan Stanley on lenacapavir potential
Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug lenacapavir. The investment bank said it was "leaning into the bull case," seeing "the potential for upward estimate revisions on lenacapavir for PrEP and further multiple expansion as the company makes progress with its
Morgan Stanley upgrades Gilead on HIV treatment growth
Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention drug Lenacapavir (PrEP) and next-gen HIV treatments.
Gilead upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley upgraded Gilead (GILD) to Overweight from Equal Weight with a price target of $113, up from $87. The firm sees the potential for
Morgan Stanley Upgrades Vir Biotechnology (VIR)
Fintel reports that on January 9, 2025, Morgan Stanley upgraded their outlook for Vir Biotechnology (NasdaqGS:VIR) from Equal-Weight to Overweight. Analyst Price Forecast Suggests 141.11% Upside As of December 23,
Vir Biotech upgraded at Morgan Stanley on cancer drug data
Morgan Stanley upgraded Vir Biotechnology (NASDAQ:VIR) to Overweight from Equal Weight on Thursday after the cancer drug developer shared initial mid-stage trial data for two antitumor agents developed using Sanofi’s (SNY) PRO-XTEN masking platform.
Morgan Stanley (MS) Earnings Expected to Grow: Should You Buy?
Morgan Stanley (MS) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture,
Morgan Stanley upgrades Vir Biotechnology to 'overweight,' raises PT to $20
Morgan Stanley (NYSE:MS) analysts have upgraded Vir Biotechnology (NASDAQ:VIR) to an "overweight" rating, shifting from "equal-weight," and have also increased their price target to $20 from $10. The analysts flagged
News Medical on MSN19h
HIV drug access remains a major challenge despite promising trial results
Promising new drugs to prevent and treat HIV have the potential to transform the response to the disease. But getting these ...
‘Pivotal step’: University of Utah biochemist’s HIV research contributes to Science’s ‘Breakthrough of the Year’
Wesley Sundquist’s lab laid foundation for development of a highly effective, long-lasting preventive measure against HIV.
Lenacapavir: The 'Breakthrough Of The Year' Drug For HIV Care
A significant breakthrough in treating the Human Immunodeficiency Virus (HIV) came recently with the US Federal Drug ...
Glassman: How Trump can meet his goal of ending AIDS
In Donald Trump’s 2019 State of the Union Address, he made “a commitment to eliminate the HIV epidemic in the United States ...
MIT Technology Review7d
Long-acting HIV prevention meds: 10 Breakthrough Technologies 2025
A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year.
Armed robbery in Revesby4d
WHO Unveils New Lenacapavir, HIV Testing Guidelines
WHO is convening a Guideline Development Group (GDG) for the development of new guidelines on the use of injectable ...
devdiscourse12d
Revolutionary HIV Drug: Lenacapavir Signals New Hope
Lenacapavir, approved by the US FDA, presents a groundbreaking advancement in the battle against HIV. Developed by Gilead ...
Mena FN4d
WHO Announces The Development Of New Guidelines For Lenacapavir And Updated HIV Testing Guidelines
(MENAFN- Caribbean News Global) GENEVA, Switzerland – WHO is convening a Guideline Development Group (GDG) for the development of new guidelines on the use of injectable lenacapavir as pre ...
The Most Important Breakthroughs of 2024
This year saw several advancements across medicine, space technology, and AI that extend our knowledge in consequential ways.
Gilead Sciences, Inc. (GILD): A Bull Case Theory
We came across a bullish thesis on Gilead Sciences, Inc. (NASDAQ:GILD) on Substack by Magnus Ofstad. In this article, we will ...